Press

MAR | Acarix publishes annual report for 2018

 

April 25, 2019

Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com. The Annual Report is found here.

For further information, please contact:
Per Persson, CEO
E-mail per.persson@acarix.com
Phone: +46 73 600 59 90

Acarix is listed on Nasdaq First North in Stockholm. Wildeco Ekonomisk Information AB (+46 8 545 271 00, info@wildeco.se) is Certified Adviser to Acarix. This information is such that Acarix (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on April 25, 2019 at 08.00 (CET).

Acarix publishes the annual report for 2018

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.